Starting July 1, 2026, millions of Medicare beneficiaries with obesity will gain access to Wegovy, Zepbound, and Foundayo for a $50 monthly copay through a new federal demonstration program. But the eligibility rules are unusually narrow: anyone already prescribed these drugs for a condition covered under Medicare Part D, such as obstructive sleep apnea or cardiovascular risk reduction, is excluded. The result is a program that targets one specific group of seniors, those whose obesity alone drives their prescription, while steering everyone else back to existing Part D channels.
Why the Bridge demonstration’s eligibility rules create immediate tension
The Centers for Medicare and Medicaid Services designed the Medicare GLP‑1 Bridge to run entirely outside the normal Part D benefit and payment flow. That structural choice carries a direct financial consequence for enrollees: the $50 monthly copay does not count toward Part D true out-of-pocket costs, known as TrOOP. Beneficiaries who enter the Bridge will not see those payments reduce their Part D spending thresholds, which means the program offers cheaper monthly access but no progress toward the catastrophic coverage phase that caps annual drug costs.
The exclusion logic is where the program gets complicated. The FDA has approved Wegovy specifically to reduce cardiovascular risk in adults with established cardiovascular disease and obesity or overweight. Separately, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. Both of those indications are coverable under Part D. CMS has explicitly stated that beneficiaries using GLP‑1 medications for any Part D-coverable indication are ineligible for the Bridge. So a senior prescribed Wegovy for cardiovascular protection or Zepbound for sleep apnea must obtain coverage through their Part D plan at standard pricing, not through the $50 demonstration.
This creates a split that will likely shape prescribing patterns. Beneficiaries whose obesity has not produced a Part D-coverable diagnosis are the program’s target population. For them, the Bridge offers a dramatic price reduction: the manufacturer net price is $245 per monthly supply, and the beneficiary pays just $50. The gap between those two figures is absorbed through the demonstration’s centralized payment structure, not through Part D plan sponsors. For patients and clinicians, that will make the initial choice of diagnosis code and indication more consequential than usual, because it determines whether the Bridge is even an option.
Covered drugs, copay mechanics, and the demonstration’s legal basis
Three drug products qualify under the Bridge. CMS lists all Wegovy formulations, Zepbound KwikPen only (excluding other Zepbound delivery formats), and all Foundayo formulations as included medications in the demonstration. The restriction to Zepbound KwikPen is a detail that prescribers and pharmacists will need to track carefully, since other Zepbound formats would not qualify for the $50 copay even if the patient otherwise meets eligibility criteria.
Operationally, the program uses a flat beneficiary contribution. Every eligible participant pays the same $50 per month for a covered GLP‑1, regardless of plan design, income, or phase of the Part D benefit. Because the Bridge is carved out from Part D, that copay does not interact with tiered formularies, deductibles, or coinsurance rates. Pharmacies will bill the demonstration rather than the patient’s Part D plan for the manufacturer-funded portion of each claim. From a beneficiary’s perspective, the experience should resemble a simple, predictable copay rather than the variable cost-sharing that often accompanies high-priced specialty drugs.
CMS is running the program under demonstration authority granted by Social Security Act Section 1860D‑42(b), which extends the demonstration provisions of the Medicare Prescription Drug, Improvement, and Modernization Act to Part D. That authority allows CMS to test alternative payment and coverage models for prescription drugs when they are expected to maintain or improve quality of care without increasing overall program spending. In announcing the initiative, CMS framed the Bridge as a temporary pathway to expand access to GLP‑1s for obesity while longer-term coverage policies evolve, highlighting in its official announcement that participation by manufacturers and pharmacies is voluntary but strongly encouraged.
Implications for beneficiaries, plans, and clinicians
For beneficiaries, the immediate trade-off is straightforward: a predictable, relatively low monthly cost for obesity treatment in exchange for giving up TrOOP credit and catastrophic coverage progress for that drug. For some, particularly those on multiple high-cost medications, remaining in traditional Part D coverage for GLP‑1s may still make financial sense, especially if they qualify for the low-income subsidy and already have reduced cost sharing.
Part D plan sponsors, meanwhile, are effectively sidelined from the pricing of these specific GLP‑1 claims for eligible beneficiaries. They will not bear the cost of the manufacturer-funded portion and will not be able to use utilization management tools within the Bridge itself. That may blunt incentives to negotiate aggressive rebates on obesity-only indications, even as plans continue to manage GLP‑1 use for Part D-coverable conditions such as cardiovascular risk reduction and obstructive sleep apnea.
Clinicians will need to navigate a more complex counseling conversation. The same drug, at the same dose, could be covered either through the Bridge or through Part D, depending on the documented indication. Explaining to patients why a cardiovascular diagnosis that clearly benefits from weight loss makes them ineligible for the $50 program, while someone with obesity alone qualifies, may prove challenging. Over time, that tension could pressure policymakers to revisit the bright line between obesity treatment and treatment of obesity-related diseases.
For now, the Medicare GLP‑1 Bridge stands as a tightly scoped experiment: generous for a narrow slice of beneficiaries, deliberately insulated from Part D’s usual mechanics, and likely to shape how clinicians document and discuss obesity in older adults.
